Ascentage Pharma Group International (AAPG)
NASDAQ: AAPG · Real-Time Price · USD
37.30
-0.53 (-1.40%)
At close: Sep 26, 2025, 4:00 PM EDT
37.33
+0.03 (0.08%)
After-hours: Sep 26, 2025, 4:10 PM EDT
AAPG Revenue
Ascentage Pharma Group International had revenue of 233.70M CNY in the half year ending June 30, 2025, with 63.77% growth. This brings the company's revenue in the last twelve months to 390.60M, down -56.75% year-over-year. In the year 2024, Ascentage Pharma Group International had annual revenue of 980.65M with 341.77% growth.
Revenue (ttm)
390.60M CNY
Revenue Growth
-56.75%
P/S Ratio
62.89
Revenue / Employee
688,894 CNY
Employees
567
Market Cap
3.43B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 980.65M | 758.67M | 341.77% |
Dec 31, 2023 | 221.98M | 12.27M | 5.85% |
Dec 31, 2022 | 209.71M | 181.80M | 651.38% |
Dec 31, 2021 | 27.91M | 15.46M | 124.18% |
Dec 31, 2020 | 12.45M | -2.06M | -14.21% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
AAPG News
- 22 days ago - Ascentage Pharma Group International (AAPG) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 5 weeks ago - Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates - GlobeNewsWire
- 5 weeks ago - Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA - GlobeNewsWire
- 7 weeks ago - Ascentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025 - GlobeNewsWire
- 2 months ago - Ascentage Pharma to Participate in Evercore China Biotech Summit - GlobeNewsWire
- 2 months ago - Ascentage Pharma Announces Closing of Placement Shares in Top-Up Placement - GlobeNewsWire
- 2 months ago - Ascentage Pharma Announces Pricing of Top-Up Placement - GlobeNewsWire
- 2 months ago - Ascentage Pharma Announces Proposed Top-Up Placement - GlobeNewsWire